Anti-PD-1/PD-L1 therapy mostly leads to myasthenic syndromes, meningitis and cranial neuropathy, and rarely encephalitis and myositis; anti-CTLA-4 treatment mostly causes meningitis and less commonly encephalitis and myositis (98). Here, CTLA4 is linked to encephalitis.